n e w s a n d v i e w s changes in methylation as opposed to differences in the proportion of cell types assayed is problematic 7 .
Whereas previous EWAS have struggled to control for such confounding factors, a likely reason for the lack of replication of early findings, the studies by De Jager et al. 5 and Lunnon et al. 4 provide compelling evidence for genuine, genome-wide significant associations between differentially methylated regions and Alzheimer's disease, and suggest that the correlatory relationship could reflect a causative one. De Jager et al. 5 adopted a three-stage study design, first screening cortical DNA for associations between methylation at 415,848 discrete CpG dinucleotides across the genome and neural plaque load, a key neuropathological feature of Alzheimer's disease, in a large cohort. They found 71 discrete CpGs corresponding to 60 differentially methylated regions, including two known Alzheimer's-associated loci identified by GWAS, ABCA7 and BIN1. Although the number of neurons sampled was not significantly different between cases and controls, the researchers included a variable to control for different proportions of cells present, combatting one of the potential sources of false positive findings mentioned above. To further strengthen the evidence, they then tested an independent replication cohort for association between the 71 significant CpGs from stage 1 and Braak staging, a postmortem measure of Alzheimer's neuropathological burden. Despite the considerably smaller sample size in this stage, they were able to replicate 12 of the CpGs (11 differentially methylated regions, as two CpGs fell close together near the RHBDF2 gene). Many of the loci that were not significant in this replication showed trends toward significance (including ABCA7 and BIN1), with similar effect sizes to those in the first cohort, suggesting that with more samples these would also validate. the epigenetic landscape of alzheimer's disease
Jenny Lord & Carlos Cruchaga
Two independent epigenome-wide association studies of Alzheimer's disease cohorts have identified overlapping methylation signals in four loci, ANK1, RPL13, RHBDF2 and CDH23, not previously associated with Alzheimer's disease. These studies also suggest that epigenetic changes contribute more to Alzheimer's disease than expected.
Alzheimer's disease is a devastating condition, currently without an effective cure, treatment or prevention, that robs people of their memories and abilities. With an estimated 26 million people living with the condition worldwide, a figure that is expected to rise as populations age, it is one of the most burdensome threats to public health today 1 . Despite this, and despite growing public attention and funding being directed into dementia research, the fundamental cause of Alzheimer's disease remains elusive. Although recent large, collaborative genome-wide association studies (GWAS) have been successful in identifying numerous genes associated with the condition 2 , the variants and mechanisms underlying these associations are generally unclear. In addition, the proportion of the genetic heritability explained by common variants is only 3-4% for each locus. Thus, it has proposed that other types of genetic variation, such as low-frequency and rare variants or epigenetic changes, may help to explain the condition 3 . In this issue of Nature Neuroscience, Lunnon et al. 4 and De Jager et al. 5 present the results of the first two large-scale, epigenome-wide association studies (EWAS) in Alzheimer's disease, with results being replicated in independent cohorts. Their results showcase one of the latest tools for dissecting the etiology of complex disorders and give new insights into the basis of Alzheimer's disease.
Epigenetics refers to changes in gene regulation brought about through modifications to the DNA's packaging proteins or the DNA molecules themselves without changing the underlying sequence 6 . Such changes are thought to be a way in which the environment can influence genetics, bringing about potentially pathogenic alterations in the way genes are expressed. Many different types of epigenetic modifications exist; these can up-or downregulate gene expression. As there is no alteration of the actual DNA sequence, resequencing efforts looking for genetic variants influencing complex traits, many of which are still poorly understood, will overlook such changes entirely. It may be that this epigenetic interface between environmental and genetic risk factors holds the key to disentangling these etiologies, and this could lead to huge leaps forward in risk prediction, diagnostics and therapeutics 7 .
Although epigenetic modifications, particularly methylation at CpG dinucleotides, which is often associated with downregulation or silencing of genes, have long been considered relevant to Alzheimer's disease pathology, empirical evidence is hard to come by, and results thus far have often been conflicting and controversial 8 . The methods for studying such modifications genome wide are still in their infancy, as are the accompanying analytical tools. Genetic methylation is thought to increase with age, complicating its study in diseases of old age such as late-onset Alzheimer's disease 9 . A particular challenge in Alzheimer's is that different populations of cells are known to have differences in epigenetic modifications; indeed, intra-individual differences between tissues far outstrip inter-individual differences in the same tissue type 10 . This is particularly problematic for Alzheimer's because a typical brain biopsy will contain multiple cell types, including neurons, astrocytes and other glia cells, all with different methylation patterns. In Alzheimer's, where there is known to be a loss of neurons, establishing disease-related npg n e w s a n d v i e w s Finally, the authors validated the findings using mRNA from brain tissue by measuring expression levels of genes near significant CpGs in the replication stage. Out of 22 nearby genes, 9 showed differences in mRNA levels, linking a meaningful biological effect to the differential methylation observed.
Lunnon et al. 4 adopted a similar strategy in their first stage, seeking associations between CpG methylation and Braak staging, this time in four different brain regions, three of which are known to be affected by Alzheimer's disease (entorhinal cortex, superior temporal gyrus and prefrontal cortex) and one that is largely left unaffected (cerebellum). Of the top ten differentially methylated CpGs in the entorhinal cortex, two fell within 91 bp of each other, close to the gene ANK1, which was also identified by De Jager et al. 5 , providing further replication for this finding. These researchers too included a correction for estimated cellular heterogeneity in the samples used. The association of both these CpGs was confirmed in the other two Alzheimer's-affected brain regions, but not in the cerebellum or pre-mortem wholeblood samples. In a further two independent replication cohorts, the two CpGs showed a significant increase in methylation at the sites associated with Braak staging. Additional CpGs, close to RHBDF2, RPL13-C10orf54 and CDH23, were also identified in both studies (Fig. 1) .
Together, these studies provide the first replicable and robust associations of differential methylation and Alzheimer's pathology. It is likely that many more of the associations will replicate given sufficient sample sizes. However, despite the compelling evidence provided by each study's robust and innovative designs, there remain limitations. Both groups used Illumina's HumanMethylation450 beadset as the main quantification method for methylation. Although this is the leading product for such studies on the market, it is far from perfect. The array only targets a small proportion of the CpG sites in the human genome (~2%), and efforts have been made to capture the ones most relevant to disease investigations, but current knowledge limits the effectiveness of the approach; the targeted CpG islands and promoter regions may not transpire to be the most significant players in this epigenetic regulation 10 . Furthermore, the array cannot distinguish between DNA methylation and DNA hydroxymethylation, which have been reported to have opposing effects on gene regulation 11 , and the analysis does not consider the many other forms of epigenetic modification that may affect disease phenotypes. Another intrinsic problem of the EWAS is that it is not clear what multiple-test correction should be used. In GWAS for common variants, the significance threshold has been set to 5.00 × 10 −8 , based on the number of independent single-nucleotide polymorphisms. It is clear that EWAS significance threshold levels should account for multiple testing. Both Lunnon et al. 4 and De Jager et al. 5 used a Bonferroni correction based on the number of sites analyzed (∼415,848, which yields a P < 1.20 × 10 −7 ). However, DNA methylation levels at nearby (within 1-2 kb) CpG sites are correlated, which suggests that a Bonferroni correction is likely to be conservative. Conversely, not all CpG sites are tested in the most common methylation arrays; thus, it is not clear how many independent CpG sites should be corrected for in a EWAS and what significance threshold should be adopted.
It also remains unclear whether the differences in methylation seen in Alzheimer's are the cause of neurodegeneration or an early consequence of neuropathological changes. Although the groups were able to demonstrate that the dysregulation of methylation is more pronounced in areas of the brain hit earlier by Alzheimer's 4, 5 , and that the changes can be seen in correlation with Alzheimer's pathology in cognitively normal, presymptomatic individuals 5 this does not establish causality. It remains to be seen how many of the other identified differentially methylated positions will replicate over time and hence whether the methodological and analytical practices in place are sufficient to address the numerous potential confounding influences.
In terms of the biology of Alzheimer's disease, the genes identified largely fit with our prior knowledge of the condition. De Jager et al. 5 were able to demonstrate that many of their differentially expressed mRNAs linked to identified CpGs connect with known Alzheimer's disease susceptibility networks derived from protein:protein interactions, genes identified by GWAS and rare variant studies. Indeed, two of the significant hits from De Jager et al. 5 resided close to ABCA7 and BIN1, genes that have been implicated in Alzheimer's disease by GWAS 12, 13 . The association of the CpGs at these genes was shown to be independent of the GWAS variants, indicating that risk loci may harbor different types of genomic variation that can independently affect disease risk. Whether this will be the case for other loci in Alzheimer's, and indeed in other complex disorders, remains to be established. 
the importance of epigenetics to complex disorders. These well-designed studies pave the way for future investigations in the field, and although there are still limitations that need to be addressed, clearly we have the ability to detect disease associated methylation differences that are correlated with biologically relevant effects on gene expression in complex disorders.
observed were correlated with isoform-specific expression of the gene in the brain.
It is also worthy of note that De Jager et al. 5 estimated the explanatory power of the significant CpGs from the first stage of their study and found that the differentially methylated CpGs together had a significantly higher explanatory power of neural plaque load than did all the known risk genes (APOE, and those identified by GWAS) for Alzheimer's disease combined (13.9% for APOE and GWAS genes, 28.7% for the CpGs cumulatively). This suggests that epigenetic dysregulation of genes may have stronger effects on risk for Alzheimer's and other complex diseases than variation in the genes themselves.
In summary, the two studies presented here provide the first robust and overlapping associations between Alzheimer's disease and differential methylation patterns in brain regions that are known to be affected by the condition. The two studies provide independent replication for a number of findings both internally and collaboratively. Although causation has not been established, it is clear that these changes occur early in the disease processindeed, before the onset of symptoms. The genes identified fit with our ever-increasing knowledge of Alzheimer's etiology, suggesting potential avenues for future diagnostics, prediction and treatment strategies for the disorder. This is some of the most compelling Notably, four new loci with differential methylation, RHBDF2, RPL13, C10orf54-CDH23 and ANK1, were independently identified in both studies, suggesting that these signals represent a real association with Alzheimer's disease risk (Fig. 1) . RHDBF2 was found to be part of the same network of interacting proteins as the Alzheimer's risk gene PTK2B, suggesting a potential role in microglia and macrophage activity. The same CpG site close to RPL13 was also differentially methylated on both studies. Networks analyses suggest that RPL13 interacts with PTK2B and APP, and it has been previously reported to be differentially expressed in Alzheimer's diseased brains as compared with controls 14 . Similarly, the same CpG site close to CDH23 and C10orf54 was found by the two groups. CDH23, but not C10orf54, was found to be differentially expressed, suggesting that CDH23 drives the initial association. However, the roles of CDH23, RPL12 and RHDBF2 in Alzheimer's disease risk are not yet clear. ANK1, although not previously linked to Alzheimer's, is a known susceptibility gene for type 2 diabetes, the parallels between which and Alzheimer's disease are receiving increasing attention 15 . Lunnon et al. 4 speculated that the brainexpressed ANK1 protein could be linked to Alzheimer's pathology via its roles in compartmentalization of the plasma membrane and showed that the methylation differences cLearance wars: PolyQ strikes back
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Polyglutamine expansion in the androgen receptor, causing X-linked spinal and bulbar muscular atrophy, impairs its function as a transcriptional coactivator regulating an extensive network of proteins involved in protein clearance. In brains suffering from neurodegenerative disease, a battle rages between the malevolent forces leading to the accumulation of misfolded disease proteins and the protective cellular machinery vying for their elimination. Given that the aberrant accumulation of disease proteins progresses relentlessly, it has often been postulated that the brain is losing the battle not only because the proteins are inherently prone to misfolding (for example, as a result of mutations), but also because the cellular pathways available to eliminate unwanted proteins are somehow compromised. But how? The answer to this question may provide new molecular therapeutic strategies for combating these largely incurable diseases. In this issue of Nature Neuroscience, Cortes et al. 1 implicate molecular defects in lysosome-mediated degradation as one of the prime features in the polyglutamine (polyQ) expansion disorder X-linked spinal and bulbar muscular atrophy (SBMA). They found that the causative protein in SBMA, the androgen receptor (AR), directly regulates cellular protein clearance transcriptionally, and polyQexpanded AR impairs this pivotal function, contributing to SBMA pathogenesis. SBMA, also known as Kennedy's disease, is an X-linked recessive disorder 2 . The disease strikes male patients in their fourth to sixth decade of life and is clinically characterized by slowly progressive muscle weakness and atrophy and by degeneration of motor neurons in the spinal cord and brainstem. SBMA was the first of nine neurodegenerative disorders found to be caused by a trinucleotide CAG repeat expansion encoding an elongated polyQ stretch, with the others being Huntington's disease, dentatorubral-pallidoluysian atrophy and six different spinocerebellar ataxias 3 . In SBMA, the polyQ tract is located near the N terminus of AR, a hormone receptor mediating transcriptional responses to androgens such as testosterone that are essential for male sexual development and characteristics. The high androgen levels in males, but not females, drive nuclear npg
